| Dr Casey Thomas Turner, MD | |
|
2811 Tieton Dr, Yakima, WA 98902-3799 | |
| (509) 575-8100 | |
| Not Available |
| Full Name | Dr Casey Thomas Turner |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 12 Years |
| Location | 2811 Tieton Dr, Yakima, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1336406792 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 16115 (Nevada) | Secondary |
| 207P00000X | Emergency Medicine | MD60866067 (Washington) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Virginia Mason Memorial | Yakima, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Yakima Valley Memorial Physicians | 1557391596 | 250 |
News Archive
Ethicon Endo-Surgery, Inc., a Johnson & Johnson company, announced today that it has reached an agreement with Hologic, Inc., and Hologic subsidiary Suros Surgical Systems, Inc., settling litigation in Ohio and dismissing pending cases in Delaware. The disputes involved patents relating to the Ethicon Endo-Surgery MAMMOTOME® Breast Biopsy System, and the Hologic ATEC and EVIVA biopsy devices. Under the terms of the agreement, Ethicon Endo-Surgery will receive $12.5 million from Hologic.
Alvine Pharmaceuticals, Inc. today announced the presentation of data from a Phase 2A trial of its lead compound, ALV003, at the 2012 Digestive Diseases Week (DDW) meeting held in San Diego, California. The study results met the primary endpoint of demonstrating that oral ALV003, administered in the context of a gluten free diet (GFD), can diminish gluten-induced intestinal mucosal injury in well-controlled celiac disease patients. The company plans to initiate a Phase 2B trial later this year.
A Los Alamos National Laboratory research team has harnessed neutrons to view for the first time the critical role that an elusive molecule plays in certain biological reactions. The effort could aid in treatment of peptic ulcers or acid reflux disease, or allow for more efficient conversion of woody waste into transportation fuels.
There's an irony at the heart of the treatment of high blood pressure. The malady itself often has no symptoms, yet the medicines to treat it — and to prevent a stroke or heart attack later — can make people feel crummy.
e-Therapeutics plc announced today interim results from its phase Ia UK study evaluating the safety, dosing and anti-tumour activity of ETS2101 (dexanabinol) in patients with advanced solid tumours.
› Verified 8 days ago
| Entity Name | Yakima Valley Memorial Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306933940 PECOS PAC ID: 1557391596 Enrollment ID: O20050818000714 |
News Archive
Ethicon Endo-Surgery, Inc., a Johnson & Johnson company, announced today that it has reached an agreement with Hologic, Inc., and Hologic subsidiary Suros Surgical Systems, Inc., settling litigation in Ohio and dismissing pending cases in Delaware. The disputes involved patents relating to the Ethicon Endo-Surgery MAMMOTOME® Breast Biopsy System, and the Hologic ATEC and EVIVA biopsy devices. Under the terms of the agreement, Ethicon Endo-Surgery will receive $12.5 million from Hologic.
Alvine Pharmaceuticals, Inc. today announced the presentation of data from a Phase 2A trial of its lead compound, ALV003, at the 2012 Digestive Diseases Week (DDW) meeting held in San Diego, California. The study results met the primary endpoint of demonstrating that oral ALV003, administered in the context of a gluten free diet (GFD), can diminish gluten-induced intestinal mucosal injury in well-controlled celiac disease patients. The company plans to initiate a Phase 2B trial later this year.
A Los Alamos National Laboratory research team has harnessed neutrons to view for the first time the critical role that an elusive molecule plays in certain biological reactions. The effort could aid in treatment of peptic ulcers or acid reflux disease, or allow for more efficient conversion of woody waste into transportation fuels.
There's an irony at the heart of the treatment of high blood pressure. The malady itself often has no symptoms, yet the medicines to treat it — and to prevent a stroke or heart attack later — can make people feel crummy.
e-Therapeutics plc announced today interim results from its phase Ia UK study evaluating the safety, dosing and anti-tumour activity of ETS2101 (dexanabinol) in patients with advanced solid tumours.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Casey Thomas Turner, MD 4700 Las Vegas Blvd N, Nellis Afb, NV 89191-6600 Ph: (702) 653-2344 | Dr Casey Thomas Turner, MD 2811 Tieton Dr, Yakima, WA 98902-3799 Ph: (509) 575-8100 |
News Archive
Ethicon Endo-Surgery, Inc., a Johnson & Johnson company, announced today that it has reached an agreement with Hologic, Inc., and Hologic subsidiary Suros Surgical Systems, Inc., settling litigation in Ohio and dismissing pending cases in Delaware. The disputes involved patents relating to the Ethicon Endo-Surgery MAMMOTOME® Breast Biopsy System, and the Hologic ATEC and EVIVA biopsy devices. Under the terms of the agreement, Ethicon Endo-Surgery will receive $12.5 million from Hologic.
Alvine Pharmaceuticals, Inc. today announced the presentation of data from a Phase 2A trial of its lead compound, ALV003, at the 2012 Digestive Diseases Week (DDW) meeting held in San Diego, California. The study results met the primary endpoint of demonstrating that oral ALV003, administered in the context of a gluten free diet (GFD), can diminish gluten-induced intestinal mucosal injury in well-controlled celiac disease patients. The company plans to initiate a Phase 2B trial later this year.
A Los Alamos National Laboratory research team has harnessed neutrons to view for the first time the critical role that an elusive molecule plays in certain biological reactions. The effort could aid in treatment of peptic ulcers or acid reflux disease, or allow for more efficient conversion of woody waste into transportation fuels.
There's an irony at the heart of the treatment of high blood pressure. The malady itself often has no symptoms, yet the medicines to treat it — and to prevent a stroke or heart attack later — can make people feel crummy.
e-Therapeutics plc announced today interim results from its phase Ia UK study evaluating the safety, dosing and anti-tumour activity of ETS2101 (dexanabinol) in patients with advanced solid tumours.
› Verified 8 days ago
David L Brown, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 2811 Tieton Dr, Yakima, WA 98902 Phone: 509-575-8000 | |
Dr. Scott W Chapman, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2811 Tieton Dr, Yakima, WA 98902 Phone: 509-575-8100 | |
Craig W. Edgar, MD00041988 Emergency Medicine Medicare: Medicare Enrolled Practice Location: 2811 Tieton Dr, Yakima, WA 98902 Phone: 509-575-8000 Fax: 509-575-8745 | |
Dr. John Barlow Tanner, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2811 Tieton Dr, Yakima, WA 98902 Phone: 509-575-8100 | |
Dr. Faye Philomena Provenza, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 110 S 9th Ave, Yakima, WA 98902 Phone: 509-575-5061 | |
Dr. Kristin Shnowske, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2811 Tieton Dr, Yakima, WA 98902 Phone: 509-575-8000 | |
Wyatt Harlan Rivas, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2811 Tieton Dr, Yakima, WA 98902 Phone: 509-575-8000 Fax: 509-575-8745 |